Menin Inhibitors: The Next Frontier in AML Therapy

In an interview with Targeted Oncology, Richard Stone, MD, Dana-Farber Cancer Institute and Harvard Medical School, highlights emerging treatment strategies in acute myeloid leukemia (AML) that are generating significant excitement among clinicians, particularly the advent of menin inhibitors.

Watch part 1 and part 2 of Dr Stone’s interview.

While FLT3 inhibitors combined with chemotherapy have been important advances, Stone notes that their use is becoming more routine and “almost passé” in the rapidly evolving AML landscape. Menin inhibitors, by contrast, represent a novel therapeutic class with strong potential to transform care for specific molecular subtypes.

These agents have already gained approval as single agents in relapsed or refractory AML, particularly for patients with KMT2A rearrangements—a subtype more commonly seen in pediatric patients—and NPM1-mutant disease, which occurs frequently in adults. Although NPM1-mutant AML is generally chemo-responsive, patients may relapse or require additional intervention, making menin inhibitors a valuable option.

Stone anticipates that the role of menin inhibitors will expand beyond relapsed disease. In the near future, they are likely to be combined with either intensive or nonintensive chemotherapy in the frontline setting for patients harboring KMT2A rearrangements or NPM1 mutations. There is also potential for these inhibitors to be explored in other genetically defined AML subsets, as precision medicine increasingly guides therapy selection.

The promise of menin inhibitors lies in their targeted mechanism, offering a therapeutic option that directly addresses the underlying genetic driver of disease while potentially minimizing toxicity compared with conventional chemotherapy. Stone’s perspective underscores a broader trend in AML treatment: a shift from one-size-fits-all chemotherapy toward highly personalized, genetics-driven approaches that improve efficacy and reduce adverse effects.

As the AML therapeutic landscape continues to evolve, menin inhibitors may soon join hypomethylating agents, venetoclax (Venclexta), and other targeted therapies as cornerstone options, offering clinicians a powerful tool to optimize outcomes in genetically defined patient populations.

Read the full interview here.